MARKET

ARQT

ARQT

Arcutis Biotherapeutics, Inc.
NASDAQ
25.08
-0.27
-1.07%
After Hours: 25.20 +0.12 +0.48% 19:30 08/21 EDT
OPEN
25.49
PREV CLOSE
25.35
HIGH
25.67
LOW
24.73
VOLUME
2.16M
TURNOVER
--
52 WEEK HIGH
31.77
52 WEEK LOW
15.10
MARKET CAP
3.15B
P/E (TTM)
116.92
1D
5D
1M
3M
1Y
5Y
1D
Top Arcutis Executive Makes Notable Move With Latest Stock Sale
TipRanks · 19h ago
Arcutis-Backed Phase 3 ZORYVE Foam Study Targets Growth in Seborrheic Dermatitis
TipRanks · 1d ago
Arcutis Biotherapeutics’ Subsidiary Arcutis Canada Secures Health Canada Approval For Roflumilast Cream In Pediatric Atopic Dermatitis Patients
Benzinga · 2d ago
Arcutis says Health Canada approves Zoryve cream 0.05% for children with AD
TipRanks · 2d ago
Arcutis Biotherapeutics (ARQT) Could Be 28% Undervalued As Profit And Guidance Improve
Simply Wall St · 3d ago
Weekly Report: what happened at ARQT last week (0810-0814)?
Weekly Report · 5d ago
Should Arcutis Biotherapeutics’ (ARQT) Strong Q2 and Higher 2026 Sales Outlook Prompt Investor Action?
Simply Wall St · 08/15 06:22
Arcutis Targets Real-World Itch Relief Data With New Phase 4 Roflumilast Study
TipRanks · 08/13 16:31
More
About ARQT
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company develops therapies against biologically validated targets and produces a pipeline for a range of inflammatory dermatological conditions. Its portfolio consists of topical and systemic treatments to treat immune-mediated dermatological diseases and conditions. Its product portfolio includes ZORYVE Roflumilast Cream, ZORYVE Roflumilast Foam, and ARQ-234. The ZORYVE Roflumilast Cream is used for the treatment of seborrheic dermatitis in individuals aged 9 years and older. The ZORYVE Roflumilast Foam for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older. The ARQ-234 is a fusion protein that is a checkpoint agonist of the CD200 Receptor (CD200R). CD200R is an immune-regulatory receptor which is an immunological checkpoint with a role in the maintenance of immune tolerance.

Webull offers Arcutis Biotherapeutics Inc stock information, including NASDAQ: ARQT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARQT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARQT stock methods without spending real money on the virtual paper trading platform.